After mTOR inhibitors: What is next?

被引：0
|
作者：
Turner, N. [1 ,2 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[2] Inst Canc Res, Sutton, Surrey, England
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S39 / S39
页数：1
相关论文
共 50 条
  • [21] What is next after anamorelin?
    Garcia, Jose M.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2017, 11 (04) : 266 - 271
  • [22] AFTER LITERACY, WHAT NEXT
    MALYA, S
    UNESCO COURIER, 1977, (02) : 23 - &
  • [23] AFTER KHRUSHCHEV - WHAT NEXT
    SWEARER, HR
    CURRENT HISTORY, 1964, 47 (279): : 257 - 265
  • [24] WHAT NEXT AFTER THE FELLOWSHIP
    MILLS, GH
    WESTON, GA
    ANAESTHESIA, 1993, 48 (05) : 444 - 445
  • [25] CDK inhibitors in cancer therapy: what is next?
    Malumbres, Marcos
    Pevarello, Paolo
    Barbacid, Mariano
    Bischoff, James R.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2008, 29 (01) : 16 - 21
  • [26] What Comes After What Comes Next
    Euchner, Jim
    RESEARCH-TECHNOLOGY MANAGEMENT, 2020, 63 (04) : 9 - 10
  • [27] What's After What's Next?
    Crews, Christian
    RESEARCH-TECHNOLOGY MANAGEMENT, 2020, 64 (01) : 65 - 66
  • [28] Is mTOR a good target for chernoprevention and what patients could benefit from mTOR inhibitors?
    Soria, J.
    EJC SUPPLEMENTS, 2005, 3 (02): : 6 - 6
  • [29] What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
    Evans, Marc
    Morgan, Angharad R.
    Yousef, Zaheer
    DIABETES THERAPY, 2019, 10 (05) : 1719 - 1731
  • [30] What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
    Marc Evans
    Angharad R. Morgan
    Zaheer Yousef
    Diabetes Therapy, 2019, 10 : 1719 - 1731
12345